After the company reported that a phase 3 trial of its most advanced clinical-stage drug panned out, shares in Global Blood Therapeutics (NASDAQ: GBT) rallied 10.7% on Wednesday.Global Blood Therapeutics is developing Voxelotor, an oral, once-daily therapy for sickle cell disease (SCD), a life-threatening chronic disease that can starve organs of blood and cause stroke.IMAGE SOURCE: GETTY IMAGES.Continue reading